MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Cross Above 50-Day Moving Average – What’s Next?

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $12.06 and traded as high as $12.91. MoonLake Immunotherapeutics shares last traded at $12.62, with a volume of 1,592,523 shares changing hands.

Key Stories Impacting MoonLake Immunotherapeutics

These are some of the MLTX stories that stood out recently:

• Positive Sentiment: Optimism ahead of the FDA’s acceptance deadline for MoonLake’s lead-drug filing appears to be supporting the stock. Filing acceptance could be an important step toward the drug’s regulatory review, though the headline does not report an FDA decision. Article: MLTX stock climbs on optimism ahead of FDA acceptance deadline for lead drug filing
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $50 price target, but lowered its 2026 and 2027 earnings estimates, reflecting expectations of larger losses. The revised outlook may temper enthusiasm even as the firm remains bullish on the shares. MoonLake Immunotherapeutics analyst estimates

Analyst Upgrades and Downgrades

MLTX has been the subject of several research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of MoonLake Immunotherapeutics in a research note on Wednesday, September 16th. Weiss Ratings raised shares of MoonLake Immunotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 21st. Chardan Capital began coverage on shares of MoonLake Immunotherapeutics in a research note on Friday, November 6th. They set a “buy” rating and a $57.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of MoonLake Immunotherapeutics in a report on Monday, October 5th. Finally, Wall Street Zen cut shares of MoonLake Immunotherapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, September 27th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.09.

MoonLake Immunotherapeutics Price Performance

The stock has a 50-day moving average of $11.98 and a two-hundred day moving average of $16.28. The company has a debt-to-equity ratio of 0.26, a quick ratio of 9.13 and a current ratio of 9.13.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, November 4th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.10). Equities research analysts forecast that MoonLake Immunotherapeutics will post -3.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its stake in MoonLake Immunotherapeutics by 227.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 40,557 shares of the company’s stock worth $475,000 after purchasing an additional 28,166 shares in the last quarter. Congress Asset Management Co. increased its stake in MoonLake Immunotherapeutics by 24.1% during the 3rd quarter. Congress Asset Management Co. now owns 223,883 shares of the company’s stock valued at $2,619,000 after purchasing an additional 43,435 shares in the last quarter. Engineers Gate Manager LP bought a new stake in MoonLake Immunotherapeutics during the 2nd quarter valued at about $2,173,000. Integrated Wealth Concepts LLC bought a new stake in MoonLake Immunotherapeutics during the 2nd quarter valued at about $39,000. Finally, Allworth Financial LP raised its holdings in MoonLake Immunotherapeutics by 156.2% in the second quarter. Allworth Financial LP now owns 1,714 shares of the company’s stock worth $33,000 after buying an additional 1,045 shares during the last quarter. Institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a Switzerland-based clinical-stage biopharmaceutical company focused on developing treatments for inflammatory skin and joint diseases. The company was established in 2021 and is headquartered in Zug. Its lead investigational medicine, sonelokimab, is a nanobody designed to inhibit the inflammatory proteins IL-17A and IL-17F. MoonLake is studying the drug as a potential treatment for conditions including hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis.